Details for Patent: 11,166,947
✉ Email this page to a colleague
Which drugs does patent 11,166,947 protect, and when does it expire?
Patent 11,166,947 protects COTEMPLA XR-ODT and is included in one NDA.
This patent has six patent family members in five countries.
Summary for Patent: 11,166,947
| Title: | Effective dosing of a child for the treatment of ADHD with methylphenidate |
| Abstract: | The present invention generally relates to treating attention-deficit disorders (e.g., ADHD) by providing an effective amount of an ADHD-effective agent to a patient in need thereof (e.g., a child). |
| Inventor(s): | Tengler; Mark (Colleyville, TX), Teuscher; Nathan (Trophy Club, TX) |
| Assignee: | Neos Therapeutics, LP (Grand Prairie, TX) |
| Application Number: | 16/346,850 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 11,166,947
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Sign Up | ||||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-002 | Jun 19, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Sign Up | ||||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-003 | Jun 19, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,166,947
| PCT Information | |||
| PCT Filed | October 31, 2017 | PCT Application Number: | PCT/US2017/059256 |
| PCT Publication Date: | May 11, 2018 | PCT Publication Number: | WO2018/085256 |
International Family Members for US Patent 11,166,947
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017353921 | ⤷ Sign Up | |||
| European Patent Office | 3585439 | ⤷ Sign Up | |||
| Japan | 2020504763 | ⤷ Sign Up | |||
| South Korea | 20190107655 | ⤷ Sign Up | |||
| South Korea | 20240033130 | ⤷ Sign Up | |||
| World Intellectual Property Organization (WIPO) | 2018085256 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
